Heinz Peter Vollmers

This inventor holds 12 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignees: Patrys Limited, Debiovision Inc.. Active years: 2008-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heinz Peter Vollmers. Retrieved from https://idiyas.com/inventor/heinz-peter-vollmers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 5)

% Patents Active = 16.7

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 1.9

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Wuerzburg, DE (2010)
Würzburg, DE (2008 - 2016)
Wurzburg, DE (2012 - 2017)

Company Filing History:

Years Active: 2008-2017

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9783599 - LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same (2017-10-10),

2. 9273125 - Human monoclonal antibody having fat-reducing effect (2016-03-01),

3. 8741296 - Adenocarcinoma specific antibody SAM-6, and uses thereof (2014-06-03),

4. 8562995 - Neoplasm specific antibodies and uses thereof (2013-10-22),

5. 8163552 - Adenocarcinoma specific antibody SAM-6, and uses thereof (2012-04-24),

6. 8124080 - Human monoclonal antibody having fat-reducing effect (2012-02-28),

7. 7947812 - Neoplasm specific antibodies and uses thereof (2011-05-24),

8. 7772372 - Neoplasm specific antibodies and uses thereof (2010-08-10),

9. 7767787 - Substance for obtaining highly effective tumor medications as well as a process (2010-08-03),

10. 7741444 - Neoplasm specific antibodies and uses thereof (2010-06-22),

11. 7611894 - Anti-idiotype antibodies of the human monoclonal antibody SC-1, and their production and use (2009-11-03),

12. 7378247 - Neoplasm-specific polypeptides and their uses (2008-05-27),

Title: Heinz Peter Vollmers: Innovator in Antibody Development

Introduction

Heinz Peter Vollmers is a notable inventor based in Würzburg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and their applications in medical treatments. With a total of 12 patents to his name, Vollmers has established himself as a key figure in innovation.

Latest Patents

Vollmers' latest patents include groundbreaking inventions such as LM-antibodies, functional fragments, and the LM-1 target antigen. These inventions provide LM-1 antibodies and their modified forms, which are crucial for diagnosing and treating various cancers. One of the methods described in his patents involves using LM-1 antibodies to treat metastasis of neoplasia, tumors, or cancers in patients. Additionally, he has developed a human monoclonal antibody that exhibits a fat-reducing effect, targeting low-density lipoproteins (LDL) and oxidized LDL (oxLDL). This polypeptide can be used in conjunction with conventional adjuvants to create effective treatments for renal diseases.

Career Highlights

Throughout his career, Vollmers has worked with several companies, including Patrys Limited and Debiovision Inc. His work has focused on advancing the understanding and application of antibodies in therapeutic contexts. His innovative approaches have led to significant advancements in the treatment of various medical conditions.

Collaborations

Vollmers has collaborated with notable professionals in his field, including Hans-Konrad Mueller-Hermelink. These collaborations have further enhanced his research and development efforts, contributing to the success of his inventions.

Conclusion

Heinz Peter Vollmers is a distinguished inventor whose work in antibody development has the potential to transform medical treatments. His innovative patents and collaborations highlight his commitment to advancing biotechnology. His contributions continue to pave the way for new therapeutic approaches in medicine.

Profile summary based on public USPTO records.